What the FDA labels say about taking them together
Aliskiren and fosinopril/hydrochlorothiazide
Fosinopril/hydrochlorothiazide's FDA label of April 28, 2024 names aliskiren in its drug interactions section; aliskiren's label does not name fosinopril/hydrochlorothiazide itself but warns about its class (ACE inhibitors, Thiazide diuretics). The fosinopril/hydrochlorothiazide label: “Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes …”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the fosinopril/hydrochlorothiazide FDA label on DailyMed (effective April 28, 2024, Aurobindo Pharma Limited).
What does the aliskiren label say about fosinopril/hydrochlorothiazide?
Aliskiren's label does not name fosinopril/hydrochlorothiazide itself; it warns about its class (ACE inhibitors, Thiazide diuretics):
Aliskiren label, warnings and precautionsIn general, avoid combined use of Tekturna with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications ( 4 ), Drug Interactions ( 7 ) and Clinical Studies ( 14.3 )].
Aliskiren label, drug interactionsIn general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min.
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the fosinopril/hydrochlorothiazide label say about aliskiren?
Fosinopril/hydrochlorothiazide label, drug interactionsDual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Fosinopril Sodium and Hydrochlorothiazide), Aurobindo Pharma Limited, effective April 28, 2024 (SPL set 35019655-9a30-4305-a262-936ad0e73071), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Fosinopril/hydrochlorothiazide | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.634 per tablet 10-12.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once